- $20.93bn
- $32.87bn
- $14.30bn
Viatris Q3 revenue and adjusted EPS beat estimates, helped by Aculys Pharma acquisition
Brief: Viatris Q3 Adjusted EPS USD 0.67 Vs. IBES Estimate USD 0.62
Focus: US Health Secretary Kennedy speeds autism drug with GSK help
Indian drugmakers Dr Reddy's, Hetero to sell generic HIV prevention drug for $40 a year
Pfizer, other drugmakers ask court to bar ex-prosecutor from price-fixing lawsuits
Colorado must face Teva's lawsuit over free allergy pen law
Brief: FDA Discontinues Manufacture Of Dymista, Nasal Spray, 137 Ug 50 Ug
U.S. STOCKS ON THE MOVE-Sempra, Occidental Petroleum, APA
Viatris Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Papa John, Elanco, Paycom,
Viatris rises after quarterly results beat estimates
Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise
U.S. STOCKS ON THE MOVE-Viatris, Ralph Lauren, Kontoor Brands
Viatris rises after quarterly results beat estimates
Brief: Viatris Q2 Adjusted EBITDA USD 1,078.8 Million
Brief: Viatris Announces Appointment Of David Simmons To The Company's Board Of Directors
US FDA advisers vote against Otsuka's PTSD combination treatment (updated)
US FDA advisers vote against Otsuka's PTSD combination treatment
U.S. STOCKS ON THE MOVE-Independent Bank, Invesco